Xeris Q2 2026 revenue exceeds $92M
Xeris Biopharma reported $92.1M in Q2 2026 revenue, up 29% year-over-year, driving a revision of full-year guidance to $385M-$390M as Recorlev sales surged.
View filing at SEC.gov →3 most recent filings and news items mentioning XERS. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/XERS/news?limit=20"
Pull XERS filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayXeris Biopharma reported $92.1M in Q2 2026 revenue, up 29% year-over-year, driving a revision of full-year guidance to $385M-$390M as Recorlev sales surged.
View filing at SEC.gov →Xeris Biopharma announced CEO John Shannon will assume the role of Chair of the Board following a transition by Marla Persky. The company also appointed Dr. Nerissa Kreher, adding a new executive with rare disease expertise to strengthen its biopharmaceutical leadership.
View filing at SEC.gov →Xeris Biopharma agreed to retire approximately $23 million of 8.00% Convertible Senior Notes due 2028 through private exchanges, reducing annual interest expenses by roughly $2 million. The transaction involves cash payment plus approximately 4.6 million common shares, strengthen
View filing at SEC.gov →